Thomas Damgaard Sandahl

Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. / Rainer, F; Horvath, A; Sandahl, T D et al.

In: Alimentary Pharmacology and Therapeutics, Vol. 47, No. 5, 03.2018, p. 657-664.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Rainer, F, Horvath, A, Sandahl, TD, Leber, B, Schmerboeck, B, Blesl, A, Groselj-Strele, A, Stauber, RE, Fickert, P, Stiegler, P, Møller, HJ, Grønbaek, H & Stadlbauer, V 2018, 'Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation', Alimentary Pharmacology and Therapeutics, vol. 47, no. 5, pp. 657-664. https://doi.org/10.1111/apt.14474

APA

Rainer, F., Horvath, A., Sandahl, T. D., Leber, B., Schmerboeck, B., Blesl, A., Groselj-Strele, A., Stauber, R. E., Fickert, P., Stiegler, P., Møller, H. J., Grønbaek, H., & Stadlbauer, V. (2018). Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Alimentary Pharmacology and Therapeutics, 47(5), 657-664. https://doi.org/10.1111/apt.14474

CBE

Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A, Groselj-Strele A, Stauber RE, Fickert P, Stiegler P, et al. 2018. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Alimentary Pharmacology and Therapeutics. 47(5):657-664. https://doi.org/10.1111/apt.14474

MLA

Vancouver

Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A et al. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Alimentary Pharmacology and Therapeutics. 2018 Mar;47(5):657-664. Epub 2017 Dec 21. doi: 10.1111/apt.14474

Author

Bibtex

@article{70ce22842bc64fd181daf3abe14c927b,
title = "Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation",
abstract = "BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease.AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14).METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months.RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8.CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.",
keywords = "Journal Article",
author = "F Rainer and A Horvath and Sandahl, {T D} and B Leber and B Schmerboeck and A Blesl and A Groselj-Strele and Stauber, {R E} and P Fickert and P Stiegler and M{\o}ller, {H J} and H Gr{\o}nbaek and V Stadlbauer",
note = "{\textcopyright} 2017 John Wiley & Sons Ltd.",
year = "2018",
month = mar,
doi = "10.1111/apt.14474",
language = "English",
volume = "47",
pages = "657--664",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation

AU - Rainer, F

AU - Horvath, A

AU - Sandahl, T D

AU - Leber, B

AU - Schmerboeck, B

AU - Blesl, A

AU - Groselj-Strele, A

AU - Stauber, R E

AU - Fickert, P

AU - Stiegler, P

AU - Møller, H J

AU - Grønbaek, H

AU - Stadlbauer, V

N1 - © 2017 John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease.AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14).METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months.RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8.CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.

AB - BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease.AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14).METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months.RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8.CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.

KW - Journal Article

U2 - 10.1111/apt.14474

DO - 10.1111/apt.14474

M3 - Journal article

C2 - 29266346

VL - 47

SP - 657

EP - 664

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -